WO2016112374A3 - Treating cancer using inhibitors of ataxia-telangiectasia mutated and rad3-related (atr) - Google Patents
Treating cancer using inhibitors of ataxia-telangiectasia mutated and rad3-related (atr) Download PDFInfo
- Publication number
- WO2016112374A3 WO2016112374A3 PCT/US2016/012797 US2016012797W WO2016112374A3 WO 2016112374 A3 WO2016112374 A3 WO 2016112374A3 US 2016012797 W US2016012797 W US 2016012797W WO 2016112374 A3 WO2016112374 A3 WO 2016112374A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rad3
- atr
- ataxia
- inhibitors
- treating cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Methods for identifying and treating cancers, e.g., Alternative Lengthening of Telomeres (ALT)-positive cancers or cancers associated with accumulation of ssDNA, using Ataxia-Telangiectasia mutated and Rad3-related (ATR) inhibitors.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562101415P | 2015-01-09 | 2015-01-09 | |
US62/101,415 | 2015-01-09 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2016112374A2 WO2016112374A2 (en) | 2016-07-14 |
WO2016112374A3 true WO2016112374A3 (en) | 2016-09-01 |
WO2016112374A9 WO2016112374A9 (en) | 2017-02-23 |
Family
ID=56356584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/012797 WO2016112374A2 (en) | 2015-01-09 | 2016-01-11 | Treating cancer using inhibitors of ataxia-telangiectasia mutated and rad3-related (atr) |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016112374A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106755430B (en) * | 2016-12-28 | 2021-06-29 | 南开大学 | Application of telomere elongation alternative mechanism (ALT) as colorectal cancer stem cell marker |
JOP20190197A1 (en) | 2017-02-24 | 2019-08-22 | Bayer Pharma AG | An inhibitor of atr kinase for use in a method of treating a hyper-proliferative disease |
IT202000005527A1 (en) * | 2020-03-16 | 2021-09-16 | Univ Degli Studi Di Trento | Therapeutic treatment of chromatinopathies |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120329047A1 (en) * | 2009-09-22 | 2012-12-27 | Roger Robert Reddel | Methods and assays for the detection of alternative lengthening of telomeres (alt) activity in cells |
WO2014140644A1 (en) * | 2013-03-15 | 2014-09-18 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii | Chemical entities |
WO2014188201A2 (en) * | 2013-05-22 | 2014-11-27 | Cancer Research Technology Limited | Treatment |
-
2016
- 2016-01-11 WO PCT/US2016/012797 patent/WO2016112374A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120329047A1 (en) * | 2009-09-22 | 2012-12-27 | Roger Robert Reddel | Methods and assays for the detection of alternative lengthening of telomeres (alt) activity in cells |
WO2014140644A1 (en) * | 2013-03-15 | 2014-09-18 | Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii | Chemical entities |
WO2014188201A2 (en) * | 2013-05-22 | 2014-11-27 | Cancer Research Technology Limited | Treatment |
Non-Patent Citations (2)
Title |
---|
FLYNN ET AL.: "Alternative Lengthening of Telomeres Renders Cancer Cells Hypersensitive to ATR Inhibitors.", SCIENCE, vol. 347, no. Issue 6219, 16 January 2015 (2015-01-16), pages 273 - 277 * |
NABETANI ET AL.: "Localization of hRad9, hHus1, hRad1, and hRad17 and Caffeine sensitive DNA Replication at the Alternative Lengthening of Telomeres-associated Promyelocytic Leukemia Body.", J BIOL. CHEM., vol. 279, no. 4, 9 April 2004 (2004-04-09), pages 25849 - 25867 * |
Also Published As
Publication number | Publication date |
---|---|
WO2016112374A2 (en) | 2016-07-14 |
WO2016112374A9 (en) | 2017-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202004769B (en) | Bisulfite-free, base-resolution identification of cytosine modifications | |
EP3622660A4 (en) | Systems and methods for crowdsourcing, analyzing, and/or matching personal data | |
MX2020011747A (en) | Gene therapies for lysosomal disorders. | |
ZA202202559B (en) | Kras g12c inhibitors and methods of using the same | |
MX2018010362A (en) | Methods and systems for evaluating tumor mutational burden. | |
MX2021012589A (en) | Piperidine derivatives as inhibitors of ubiquitin specific protease 7. | |
MX2017003478A (en) | Anti-fgfr2/3 antibodies and methods using same. | |
MX2018016057A (en) | Compositions and methods for treating cardiovascular disease. | |
MX2020011745A (en) | Gene therapies for lysosomal disorders. | |
MX2018009773A (en) | Heteroaryl inhibitors of pad4. | |
MX2020005213A (en) | Mk2 inhibitors and uses thereof. | |
MX2018016038A (en) | Compounds and methods for modulating rna function. | |
MX2018006632A (en) | Bicyclic inhibitors of pad4. | |
WO2016065349A3 (en) | Short non-coding protein regulatory rnas (sprrnas) and methods of use | |
MX2017014735A (en) | Pd-l1 promoter methylation in cancer. | |
MX2018005461A (en) | Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity. | |
PH12018500887A1 (en) | Anti-htra1 antibodies and methods of use thereof | |
MY181693A (en) | Dual quencher probes | |
MX2020006297A (en) | Cd19 variants. | |
MX2017005888A (en) | Devices, systems, and methods for the detection of analytes. | |
MX2022003212A (en) | Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use. | |
EP3693742A3 (en) | Methods of detecting prostate cancer | |
MX2018003301A (en) | Pcna inhibitors. | |
WO2016112374A3 (en) | Treating cancer using inhibitors of ataxia-telangiectasia mutated and rad3-related (atr) | |
MX2019006552A (en) | Gene therapy for mucopolysaccharidosis, type i. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16735537 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16735537 Country of ref document: EP Kind code of ref document: A2 |